DelveInsight’s “Eosinophilic Esophagitis Market Insights, Epidemiology, and Market Forecast-2036” report delivers an in-depth understanding of Eosinophilic Esophagitis, historical and forecasted epidemiology, as well as the Eosinophilic Esophagitis market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Discover Key Insights into the Eosinophilic Esophagitis Market with DelveInsight’s In-Depth Report @ Eosinophilic Esophagitis Market Size
Key Takeaways from the Eosinophilic Esophagitis Market Report
- In May 2022, the US FDA approved DUPIXENT (dupilumab) to treat EoE in adults and pediatric patients 12 years and older, and in January 2024, expanded approval for pediatric patients aged 1 to 11 years weighing at least 15 kg.
- According to DelveInsight’s estimates, in the 7MM, the US accounted for the highest diagnosed prevalent cases of eosinophilic esophagitis in 2025, with around 512,000 cases, representing approximately 72% of the total market.
- Eosinophilic Esophagitis predominantly affected males, with approximately 332,000 males diagnosed compared to 179,000 females in 2025 in the US.
- In the EU4 and the UK, individuals over the age of 18 were the most affected by Eosinophilic Esophagitis, with approximately 395,000 cases reported in 2025.
- In 2025, the total market size of EoE in the US was approximately USD 650 million and is projected to reach USD 2,800 million by 2036, growing at 14% CAGR.
- In 2025, DUPIXENT led the US EoE treatment market and is projected to retain its position as the dominant market leader through 2036.
- The leading Eosinophilic Esophagitis companies such as AstraZeneca, Amgen, Ellodi Pharmaceuticals, Revolo Biotherapeutics, Phathom Pharmaceuticals, Uniquity Bio, EsoCap AG, DBV Technologies, Eupraxia Pharmaceuticals, and others.
- Promising Eosinophilic Esophagitis Therapies such as Tezepelumab (TEZSPIRE), APT-1011, IRL201104, Vonoprazan (VOQUEZNA), Solrikitug (NSI-8226), ESO-101, EP-104GI, and others.
Stay ahead in the Eosinophilic Esophagitis Therapeutics Market with DelveInsight’s Strategic Report @ Eosinophilic Esophagitis Market Outlook
Eosinophilic Esophagitis Epidemiology Segmentation in the 7MM
- Total Diagnosed Prevalent Cases of Eosinophilic Esophagitis
- Gender-specific Cases of Eosinophilic Esophagitis
- Age-specific Cases of Eosinophilic Esophagitis
- Treated Cases of Eosinophilic Esophagitis
Download the report to understand which factors are driving Eosinophilic Esophagitis epidemiology trends @ Eosinophilic Esophagitis Prevalence
Eosinophilic Esophagitis Pipeline Analysis
• Tezepelumab (TEZSPIRE): AstraZeneca and Amgen
Tezepelumab is being developed by AstraZeneca in collaboration with Amgen as a first-in-class human monoclonal antibody that inhibits the action of TSLP. This key epithelial cytokine sits at the top of multiple inflammatory cascades and is critical in the initiation and persistence of allergic, eosinophilic, and other types of airway inflammation. In October 2021, tezepelumab was granted Orphan Drug Designation by the FDA for the treatment of EoE. The Phase III CROSSING trial is evaluating tezepelumab in patients with EoE, with data anticipated in the second half of 2026.
• APT-1011 (fluticasone propionate): Ellodi Pharmaceuticals
APT-1011 is a novel, once-daily, orally disintegrating tablet designed specifically to deliver fluticasone propionate to the esophageal mucosa to exert local anti-inflammatory effects with low systemic absorption. The successful completion of FLUTE 1 (Phase IIb study) and FLUTE 2 (Phase III study) has facilitated the initiation of FLUTE 3 (ongoing second Phase III study). APT-1011 has received Orphan Drug Designation from the FDA and EMA, and also received Fast Track Designation from the FDA in 2021, providing a competitive edge as it is expected to be the first to reach the market.
• IRL201104: Revolo Biotherapeutics
IRL201104 is an immunomodulator being developed by Revolo Biotherapeutics for adults with active EoE. This sublingual tablet is designed for patients with swallowing difficulties, offering a unique administration route. In August 2025, Revolo Biotherapeutics announced its decision to accelerate the advancement of the sublingual tablet to enter the clinic in 2026.
• Solrikitug (NSI-8226): Uniquity Bio
Solrikitug is a TSLP inhibitor being developed by Uniquity Bio for adults with EoE via subcutaneous administration. This therapy represents another approach to targeting the thymic stromal lymphopoietin pathway in eosinophilic esophagitis.
• ESO-101: EsoCap AG
ESO-101 is a glucocorticoid receptor agonist being developed by EsoCap AG for adults with EoE via oral administration. This therapy aims to control esophageal inflammation and provide symptom relief.
• EP-104GI: Eupraxia Pharmaceuticals
EP-104GI is a glucocorticoid receptor agonist delivered as a once-yearly submucosal injection, offering a unique dosing approach. In May 2025, Eupraxia Pharmaceuticals announced positive treatment outcomes from its ongoing RESOLVE Phase Ib/IIa trial, with 9-month data demonstrating sustained or improved treatment outcomes.
Eosinophilic Esophagitis Drugs Market Insights
Currently, three therapies are approved for EoE: Budesonide oral dispersible tablet (JORVEZA) approved in Europe in 2018 for adults, dupilumab (DUPIXENT) the first and only biologic therapy approved in the US in 2022 and Europe in 2023 for patients age 1 and older, and budesonide oral suspension (EOHILIA) approved in the US in 2024 for patients 11 years and older. Dupilumab covers a broader patient population and holds a strong market position over these more restricted therapies.
First-line treatment for EoE typically involves proton pump inhibitors; however, many patients do not achieve adequate response. Management often progresses to swallowed topical corticosteroids or biologics, alongside non-pharmacologic options such as food elimination diets and esophageal dilation, highlighting the need for a multimodal treatment approach.
Several companies are developing drug candidates poised to reshape the EoE market during the forecast period. Key approaches under investigation include thymic stromal lymphopoietin inhibitors (TEZSPIRE and Solrikitug), glucocorticoid receptor agonists (APT-1011, ESO-101, and EP-104GI), and immunomodulators (IRL201104), among others. Companies are focusing on novel approaches and diverse administration routes to address unmet needs and improve patient symptoms.
Get In-Depth Knowledge on Eosinophilic Esophagitis Market Trends and Forecasts with DelveInsight @ Eosinophilic Esophagitis Treatment Market
Eosinophilic Esophagitis Companies
AstraZeneca, Amgen, Ellodi Pharmaceuticals, Revolo Biotherapeutics, Phathom Pharmaceuticals, Uniquity Bio, EsoCap AG, DBV Technologies, Eupraxia Pharmaceuticals, Sanofi, Regeneron Pharmaceuticals, Takeda, Dr. Falk Pharma GmbH, and others.
Eosinophilic Esophagitis Market Outlook
Eosinophilic Esophagitis is an emerging chronic inflammatory disease of the esophagus characterized by upper gastrointestinal symptoms, including dysphagia and esophageal food impaction. The histopathological manifestations involve intraepithelial infiltration of eosinophils and remodeling of the esophageal epithelium, which can lead to strictures and narrow-caliber esophagus.
The Eosinophilic Esophagitis Market Size was valued at ~USD 901 million in 2025 and is anticipated to reach ~USD 3,543 million growing with a significant CAGR of 12.9% during the study period (2022-2036). In 2025, the United States held the largest market share for EoE among the 7MM, accounting for approximately 72% of the total market with an estimated market size of USD 650 million.
Scope of the Eosinophilic Esophagitis Market Report
- Coverage- 7MM
- Study Period- 2022-2036
- Forecast Period- 2026-2036
- Eosinophilic Esophagitis Companies- AstraZeneca, Amgen, Ellodi Pharmaceuticals, Revolo Biotherapeutics, Phathom Pharmaceuticals, Uniquity Bio, EsoCap AG, DBV Technologies, Eupraxia Pharmaceuticals, and others
- Eosinophilic Esophagitis Therapies- Tezepelumab (TEZSPIRE), APT-1011, IRL201104, Vonoprazan (VOQUEZNA), Solrikitug (NSI-8226), ESO-101, EP-104GI, and others
- Eosinophilic Esophagitis Market Access & Reimbursements, Unmet Needs and Perspectives
- Eosinophilic Esophagitis SWOT Analysis and KOL Views
Unlock Strategic Insights with DelveInsight’s Comprehensive Eosinophilic Esophagitis Market Report @ Eosinophilic Esophagitis Market Drivers and Barriers
Table of Contents
- Key Insights
- Report Introduction
- Executive Summary
- Key Events
- Epidemiology and Market Forecast Methodology
- Eosinophilic Esophagitis Market Overview at a Glance
- Disease Background and Overview of Eosinophilic Esophagitis
- Treatment of Eosinophilic Esophagitis
- Eosinophilic Esophagitis: 7MM Analysis
- Patient Journey of Eosinophilic Esophagitis
- Marketed Therapies
- Emerging Therapies
- Eosinophilic Esophagitis: 7MM Analysis (Market Analysis Section)
- Unmet Needs of Eosinophilic Esophagitis
- SWOT Analysis of Eosinophilic Esophagitis
- KOL Views of Eosinophilic Esophagitis
- Market Access and Reimbursement of Eosinophilic Esophagitis
- Appendix
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Kanishk
